You can buy or sell PIRS and other stocks, options, ETFs, and crypto commission-free!
Pieris Pharmaceuticals, Inc. Common Stock, also called Pieris Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Read More Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Simply Wall StMar 14
Is Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) A Volatile Stock?
If you own shares in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The other type, w...
Yahoo FinanceFeb 26
Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasiz
NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (CAG), Pieris Pharmaceuticals, Inc. (PIRS), ArQule, Inc. (ARQL), MoneyGram International Inc. (MGI), Internap Corporation (INAP), and TIM Participacoes S.A. (TSU), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst ...
Stock Price, News, & Analysis for Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anti...
-$0.15 per share
-$0.21 per share